Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 2, 2009, Pages 196-207

  Goeree, Ron ^a,b   Bowen, James M ^a   Blackhouse, Gord ^a   Lazzam, Charles ^c   Cohen, Eric ^d,e   Chiu, Maria ^f   Hopkins, Rob ^a   Tarride, Jean Eric ^a   Tu, Jack V ^d,g  

^a MCMASTER UNIVERSITY   (Canada)

^b Programs for Assessment of Technology in Health PATH Research Institute   (Canada)

^c Trillium Health Centre Missassauga   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e Sunnybrook Health Sciences Centre ^*

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bare metal stents; Cost utility analysis; Costs and cost analysis; Drug eluting stents; Economic evaluation

Indexed keywords

BARE METAL STENTS; COHORT STUDIES; COST DATA; COST-UTILITY ANALYSIS; DECISION ANALYTIC MODELING; DRUG-ELUTING STENTS; ECONOMIC EVALUATION; ECONOMIC EVALUATIONS; FIELD EVALUATION; HIGH-RISK PATIENTS; METAL STENTS; ONTARIO; PROBABILISTIC MODELS; PROSPECTIVE STUDY; QUALITY OF LIFE; REAL-WORLD; RELATIVE PRICES; RESOURCE UTILIZATIONS; REVASCULARIZATION; RISK FACTORS; VALUE FOR MONIES;

ARTIFICIAL ORGANS; COST ACCOUNTING; COST EFFECTIVENESS; COSTS; METAL ANALYSIS; METALS; MODEL CHECKING; PROBABILITY DISTRIBUTIONS; RISK PERCEPTION; SENSITIVITY ANALYSIS; STOCHASTIC MODELS; UNCERTAINTY ANALYSIS;

COST BENEFIT ANALYSIS;

ADULT; ARTICLE; BARE METAL STENT; CANADA; COMORBIDITY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; PROBABILITY; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; REVASCULARIZATION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; MULTICENTER STUDY; RISK; STENT;

AGED; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; ONTARIO; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RISK; STENTS;

EID: 67549129363     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309090254     Document Type: Article

References (56)

1. Austin PC, Mamdani MM. A comparison of propensity score methods: Acase-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25:2084-2106.
2. Bagust A, Grayson AD, Palmer ND, et al. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: Costutility study. Heart. 2006;92:68-74. (Pubitemid 43021858)
3. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: Results from the TAXUS-IV Trial. J Am Coll Cardiol. 2006;48:253-261. (Pubitemid 44026660)
4. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992-2000.
5. Bowen J, Hopkins R, Chiu M, et al. Clinical and costeffectiveness analysis of drug eluting stents compared to bare metal stents for percutaneous coronary interventions in Ontario: Final report. Hamilton (ON): Program for Assessment of Technology in Health, McMaster University / St. Joseph's Healthcare Hamilton; 2007.
6. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
7. Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care. 2005;21:326-333. (Pubitemid 41099213)
8. Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. Costeffectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent Kosten Effektivit äts Trial (BASKET): An 18-month analysis. Lancet. 2007;370:1521-1588. (Pubitemid 350018894)
9. Cardiac Care Network (CCN) of Ontario. 2008.
10. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation. 2004;110:508-514. (Pubitemid 39031165)
11. Curfman GD. Sirolimus-eluting coronary stents. N Engl J Med. 2002;346:1770-1771.
12. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168. (Pubitemid 46089732)
13. Ekman M, Sjogren I, James S. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scand Cardiovasc J. 2006;40:17-24. (Pubitemid 43203345)
14. Galanaud JP, Delavennat J, Durand-Zaleski I. A break-even price calculation for the use of sirolimus-eluting stents in angioplasty. Clin Ther. 2003;25:1007-1016. (Pubitemid 36459705)
15. Goeree R, Levin L. Building bridges between academic research and policy formulation: The PRUFE framework - an integral part of Ontario's evidence-based HTPA process. Pharmacoeconomics. 2006;24:1143-1156. (Pubitemid 44683370)
16. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol. 2004;43:513-518. (Pubitemid 38229518)
17. Greenberg D, Cohen DJ. Examining the economic impact of restenosis: Implications for the cost-effectiveness of an antiproliferative stent. Z.Kardiol. 91[Suppl 3], 137-143. 2002. (Pubitemid 34809739)
18. Grines CL, Bonow RO, Casey DEJr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734-739. (Pubitemid 46210116)
19. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969-1976. (Pubitemid 30342882)
20. Hill R, BagustA,BakhaiA, et al. Coronary artery stents:Arapid systematic review and economic evaluation. Health Technol Assess. 2004;8:iii-iiv. (Pubitemid 39591602)
21. Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1-242.
22. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634-640.
23. Institute of Clinical and Evaluative Sciences. Toronto: ICES; 2008.
24. Kaiser C, Brunner-La Rocca HP, et al. Incremental costeffectiveness of drug-eluting stents compared with a thirdgeneration bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366:921-929. (Pubitemid 41265666)
25. Kastrati A, Hall D, Schomig A. Long-term outcome after coronary stenting. Curr Control Trials Cardiovasc Med. 2000;1:48-54.
26. Kuukasjarvi P, Rasanen P,Malmivaara A, et al. Economic evaluation of drug-eluting stents: A systematic literature review and model-based cost-utility analysis. Int J Technol Assess Health Care. 2007;23:473-479. (Pubitemid 47586912)
27. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019. (Pubitemid 46376801)
28. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-481.
29. Ligthart S, Vlemmix F, Dendukuri N, et al. The cost-effectiveness of drug-eluting stents: A systematic review. CMAJ. 2007;176:199-205. (Pubitemid 46168380)
30. Lord SJ, Howard K, Allen F, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust. 2005;183:464-471. (Pubitemid 41671779)
31. Mahieu J, De Ridder A, De Graeve D, Vrints C, Bosmans J. Economic analysis of the use of drug-eluting stents from the perspective of Belgian health care. Acta Cardiol. 2007;62:355-365. (Pubitemid 47310621)
32. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342-352. (Pubitemid 351159233)
33. Medical Advisory Secretariat, Cohen E. Review of drug-eluting coronary stents. Toronto, Ontario, Canada: Ontario Ministry of Health and Long-term Care; 2003 Jan 7.
34. Medical Services Advisory Committee. Drug-eluting stents. Canberra (Australia): Commonwealth of Australia; 2005.
35. Mittmann N, Brown A, Seung SJ, et al. Economic evaluation of drug eluting stents [Technology Report no 53]. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2005.
36. Morice MC, Serruys PW, Sousa JE, et al. Randomized Study with the Sirolimus-Coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
37. Moses JW, Leon MB, Popma JJ, et al. SIRIUS I. Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
38. Oliva G, Espallargues M, Pons JM. Antiproliferative drugeluting stents: Systematic review of the benefits and estimate of economic impact. Rev Esp Cardiol. 2004;57:617-628. (Pubitemid 39144663)
39. Ong AT, Daemen J, van Hout BA, et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: Results from the RESEARCH Registry. Eur Heart J. 2006;27:2996-3003. (Pubitemid 44950444)
40. Ontario Case Costing Initiative. Ontario Case Costing Initiative. Toronto: 2008.
41. Ontario Health Technology Advisory Committee. Toronto: OHTAC; 2007.
42. Ontario Ministry of Health and Long-Term Care. Schedule of benefits: Physician services under the Health Insurance Act- effective June 3, 2008. Toronto: The Ministry; 2006.
43. OntarioMinistry of Health and Long-Term Care. Ontario Drug Benefit Formulary/ComparativeDrug Index-effective June 27, 2008. Toronto: The Ministry; 2007.
44. Polanczyk CA, Wainstein MV, Ribeiro JP. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil. Arq Bras Cardiol. 2007;88:464-474.
45. Programs for Assessment of Technology in Health (PATH) Research Institute. Ontario: PATH; 2008.
46. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 1999;341:1957-1965.
47. Rinfret S, Cohen DJ, Tahami Monfared AA, et al. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: An analysis from the C-SIRIUS trial. Am J Cardiovasc Drugs. 2006;6:159-168 (Pubitemid 43961767)
48. Ruffy R, Kaden RJ. Projected health and economic benefits of the use of sirolimus-eluting coronary stents. Adv Stud Med. 2003;3:S602-S611. (Pubitemid 36830661)
49. Russell S, anzas F, Mainar V. Economic impact of the Taxus coronary stent: Implications for the Spanish healthcare system. Rev Esp Cardiol. 2006;59:889-896. (Pubitemid 44741793)
50. Schampaert E, Cohen EA, Schluter M, et al. SIRIUS I. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-1115. (Pubitemid 38352997)
51. Schofer J, Schluter M, Gershlick AH, et al. SIRIUS I. Sirolimuseluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099. (Pubitemid 37222332)
52. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronaryartery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124. (Pubitemid 32285232)
53. Shrive FM, Manns BJ, Galbraith PD, et al. Economic evaluation of sirolimus-eluting stents. CMAJ. 2005;172:345-351.
54. Tarricone R, Marchetti M, Lamotte M, et al. What reimbursement for coronary revascularization with drug-eluting stents (Structured abstract). Eur J Health Econ. 2004;5:309-316. (Pubitemid 40543182)
55. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drugeluting stents in Ontario. N Engl J Med. 2007;357:1393-1402. (Pubitemid 47541971)
56. van Hout BA, Serruys PW, Lemos PA, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial. Heart. 2005;91:507-512.